Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies. Harbour is getting about $90 million up ...
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback